Kisspeptin (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously. This schedule follows a conservative titration to assess individual response. For 10 unit (0.10 mL) or smaller administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 3.33 mg/mL, 1 unit = 0.01 mL » 33.3 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions with desiccant if possible.
• Reconstituted: refrigerate at 2 to 8 °C; stable up to ~4 weeks; avoid freeze-thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (Kisspeptin, 10 mg each):

• 8 weeks: ~1 vial. 12 weeks: ~2 vials. 16 weeks: ~3 vials.

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 to 16 weeks (1 to 3 vials): 1 bottle.

Alcohol Swabs:

• Per week: 14 swabs.
• 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• Discard bacteriostatic water after 28 days once opened.

How This Works

Kisspeptin is an upstream trigger for the reproductive hormone cascade. Upon subcutaneous injection, kisspeptin rapidly binds to kisspeptin receptors (GPR54) on GnRH neurons in the hypothalamus, causing immediate release of GnRH. This in turn stimulates the anterior pituitary to secrete LH and FSH, which act on the gonads to boost sex steroid production and support gametogenesis. Importantly, kisspeptin's action is GnRH-dependent: if GnRH release is blocked, kisspeptin cannot induce LH/FSH secretion. This confirms that kisspeptin works by unlocking the body's own GnRH stores, providing a more physiologic pattern of hormone release compared to direct GnRH or hCG administration.

Benefits & Side Effects

Observations from preclinical and clinical literature.

• Physiological sex hormone stimulation: increases endogenous testosterone and estrogen levels by

amplifying the body's own LH/FSH signals without suppressing the HPG axis.

• Fertility restoration: shows promise in functional hypothalamic amenorrhea by rekindling GnRH/LH

pulsatility and resuming menstrual cycles.

• IVF ovulation trigger: can induce robust LH surge to mature oocytes while potentially lowering the risk

of ovarian hyperstimulation syndrome compared to traditional hCG triggers.

• Safety profile: generally well tolerated; occasional mild injection-site reactions (redness, itch) may occur

with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain adequate nutrition and healthy body weight to support endogenous hormone production.
• Prioritize sleep and stress management, as these factors significantly impact the HPG axis.
• Monitor for changes in reproductive function or hormone-related symptoms.
• Consider combining with appropriate lifestyle interventions for conditions of hypothalamic suppression.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Emerging Therapeutic Potential of Kisspeptin and Neurokinin B (Endocrine Reviews).
2. Kisspeptin-54 triggers egg maturation in IVF with reduced OHSS risk (J Clinical Investigation).
3. Functional hypothalamic amenorrhea: restoration of GnRH pulsatility (Endocrine Reviews).
4. Kisspeptin mechanism: GPR54 receptor binding and GnRH release (Endocrine Reviews). KLOW (80 mg blend (GHK-Cu 50 + BPC-157 10 + TB-500 10 + KPV 10) vial) Once-daily subcutaneous protocol for combined regenerative and anti-inflammatory peptide research. KLOW is a multi-peptide blend combining TB-500 (10 mg), BPC-157 (10 mg), KPV (10 mg), and GHK-Cu (50 mg) for a total of 80 mg per vial. TB-500 promotes wound healing, angiogenesis, and tissue repair. BPC-157 supports tendon, ligament, and muscle healing. KPV is an anti-inflammatory tripeptide that modulates NF-kB signaling. GHK-Cu supports collagen synthesis and tissue regeneration. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements. Protocol Overview Concise summary of the regimen. Goal: Support tissue repair, reduce inflammation, and promote regeneration through synergistic peptide action. Schedule: Daily subcutaneous injections for 8 to 12 weeks (extend to 16 weeks if desired). Dose Range: Gradual titration from low to moderate doses based on individual response. Reconstitution: 3.0 mL per 80 mg vial (~26.7 mg/mL total). Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze-thaw. Dosing & Reconstitution Guide Standard / gradual approach (3 mL = ~26.7 mg/mL total). DAILY DOSE (PER WEEK UNITS PER INJECTION COMPONENT) TB-500: 250 mcg / BPC: 250 / Weeks 1 to 2 7.5 units (0.075 mL) KPV: 250 / GHK-Cu: 1.25 mg TB-500: 500 mcg / BPC: 500 / Weeks 3 to 4 15 units (0.15 mL) KPV: 500 / GHK-Cu: 2.5 mg TB-500: 750 mcg / BPC: 750 / Weeks 5 to 8 22.5 units (0.225 mL) KPV: 750 / GHK-Cu: 3.75 mg TB-500: 500 mcg / BPC: 500 / Weeks 9 to 12 (Maintenance) 15 units (0.15 mL) KPV: 500 / GHK-Cu: 2.5 mg Frequency: Inject once daily subcutaneously. For 10 unit (0.10 mL) or smaller administrations during initial weeks, consider 30- or 50-unit insulin syringes for improved readability. Reconstitution Steps
5. Draw 3.0 mL bacteriostatic water with a sterile syringe.
6. Inject slowly down the vial wall; avoid foaming.
7. Gently swirl until dissolved (do not shake).
8. Label and refrigerate at 2 to 8 °C, protected from light. Syringe math reference: with 3.0 mL reconstitution and 80 mg total, concentration is 26.67 mg/mL. TB-500, BPC-157, KPV each at 3.33 mg/mL (33.3 mcg per unit); GHK-Cu at 16.67 mg/mL (166.7 mcg per unit). 1 unit = 33.3 mcg each of TB-500, BPC-157, KPV + 166.7 mcg GHK-Cu. Storage Instructions Proper storage preserves peptide quality. • Lyophilized: store at -20 °C in dry, dark conditions; minimize moisture exposure. • Reconstituted: refrigerate at 2 to 8 °C; use within 14 to 28 days; avoid freeze-thaw. • Allow vials to reach room temperature before opening to reduce condensation uptake. Supplies Needed Plan based on an 8 to 16 week daily protocol with gradual titration. Peptide Vials (KLOW, 80 mg each): • 8 weeks: ~3 vials. 12 weeks: ~4 vials. 16 weeks: ~5 vials. Insulin Syringes (U-100): • Per week: 7 syringes (1/day). • 8 weeks: 56. 12 weeks: 84. 16 weeks: 112. Bacteriostatic Water (10 mL bottles): • 8 weeks (3 vials): 1 bottle. 12 weeks (4 vials): 2 bottles. 16 weeks (5 vials): 2 bottles. Alcohol Swabs: • Per week: 14 swabs. • 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count). Important Notes Practical considerations for consistency and safety. • Use new sterile insulin syringes for each injection; dispose in a sharps container. • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation. • Inject slowly; wait a few seconds before withdrawing the needle. • Document daily dose and site rotation to maintain consistency. • This multi-peptide blend may provide broader regenerative support than single-peptide protocols. How This Works KLOW combines four peptides with complementary mechanisms of action. TB-500 (Thymosin Beta-4) promotes angiogenesis, cell migration, and tissue repair by regulating actin. BPC-157 is a gastric pentadecapeptide that supports tendon, ligament, and muscle healing through enhanced angiogenesis and growth factor modulation. KPV is a C-terminal tripeptide fragment of a-MSH with potent anti-inflammatory properties: it inhibits NF-kB signaling and reduces pro-inflammatory cytokines without melanotropic effects. GHK-Cu is a naturally occurring copper peptide that stimulates collagen and elastin synthesis, promotes wound healing, and modulates gene expression related to tissue remodeling. Potential Benefits and Side Effects Observations from preclinical and early-stage research. • Accelerated tissue repair and wound healing through multiple complementary pathways. • Reduced inflammation via NF-kB inhibition and cytokine modulation. • Enhanced collagen synthesis and connective tissue support. • Promotion of angiogenesis and improved blood flow to healing tissues. • Potential support for musculoskeletal recovery and joint health. • Mild injection-site reactions (redness, irritation) may occur with subcutaneous administration. • Occasional lightheadedness reported with some peptides due to vasodilatory effects. • Limited human clinical data; most safety observations derive from preclinical studies. Lifestyle Factors Complementary strategies for best outcomes. • Pair with a balanced, protein-forward diet tailored to support tissue repair and recovery. • Combine resistance training and mobility work to reinforce musculoskeletal adaptations. • Prioritize sleep and stress management to optimize the body's natural regenerative processes. • Stay well-hydrated to support peptide absorption and overall metabolic function. Injection Technique General subcutaneous guidance from clinical best-practice resources.
9. Clean the vial stopper and skin with alcohol; allow to dry.
10. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
11. Do not aspirate for subcutaneous injections; inject slowly and steadily.
12. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
13. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy. Recommended Source NTN Performance recommends Amino Club for high-purity KLOW (80 mg blend (GHK-Cu 50 + BPC-157 10 + TB-500 10 + KPV 10)). If unavailable at Amino Club, our trusted backup is ION Peptide. Why Amino Club? • Lab-verified purity with batch Certificates of Analysis. • Consistent handling and documentation standards. • Reliable fulfillment with cold-chain integrity. Primary: KLOW at Amino Club (code PROFIT). Backup: KLOW at ION Peptide (code PROFIT). References Source citations for further reading.
14. Philp D et al. Thymosin beta 4 accelerates wound healing (1999).
15. Emerging use of BPC-157 in orthopaedic sports medicine: systematic review (HSS Journal).
16. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Gastroenterology).
17. Pickart L. Regenerative and protective actions of the GHK-Cu peptide (Int J Mol Sci).